Metoclopramide Hydrochloride side effects: what 76,703 FDA adverse event reports show
Drug class
Not stated in label
Who reports
76,703 reports · 89% serious · 9,885 with death outcome · 63% female
Used for
Metoclopramide tablets are indicated for the: Treatment for 4 to 12 weeks of symptomatic, documented gastroesophageal reflux in adults who fail to respond to conventional therapy. Relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
What it is
Metoclopramide hydrochloride, USP, the active ingredient of metoclopramide tablets, USP is a dopamine-2 receptor antagonist. Metoclopramide hydrochloride (metoclopramide monohydrochloride monohydrate) is a white or practically white, crystalline, odorless or practically odorless powder.
Boxed warning
TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].
Causality screen of the 40 strongest signals
What the badges mean
- Labeled — boxed warning The term (or its clinical synonym) appears in the FDA boxed warning: causality is regulator-recognised and considered serious.
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Likely indication confounding The term appears in the label's indications: reports probably describe the disease being treated (or its progression), not a drug effect. Classic confounding by indication.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,181 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Family stress | 1,934 | 446.1 415.0–479.6ROR 457.6 · calibrated p 1e-13 ✓ | 168.1 EB05 161.9 · IC025 +7.3 3/3 methods agree | Not in label — unassessed | serious n=1,934 | no trial arm names this drug |
| Tardive dyskinesia (persistent involuntary movements) | 16,218 | 366.3 358.2–374.7ROR 464.3 · calibrated p 1e-13 ✓ | 155.6 EB05 153.6 · IC025 +7.2 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 115.7 · 79% consumer | no trial arm names this drug |
| Lymphoid tissue hypoplasia | 84 | 358.3 258.5–496.7ROR 358.7 · calibrated p 6e-12 ✓ | 149.0 EB05 124.1 · IC025 +6.0 3/3 methods agree | Not in label — unassessed | serious n=84 · ♀ 0% (drug 63%) | no trial arm names this drug |
| Extrapyramidal disorder | 12,922 | 293.5 286.5–300.6ROR 352.7 · calibrated p 2e-12 ✓ | 140.8 EB05 138.7 · IC025 +7.1 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 9.3 · serious PRR 97.3 · 71% consumer | no trial arm names this drug |
| Thymus hypoplasia | 85 | 268.7 199.0–363.0ROR 269.0 · calibrated p 7e-11 ✓ | 131.0 EB05 109.2 · IC025 +5.9 3/3 methods agree | Not in label — unassessed | serious n=85 · ♀ 0% (drug 63%) | no trial arm names this drug |
| Dystonia | 7,115 | 158.1 153.7–162.7ROR 174.2 · calibrated p 1e-9 ✓ | 99.9 EB05 98.0 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious PRR 69.7 | no trial arm names this drug |
| Multiple injuries | 2,243 | 148.8 141.4–156.6ROR 153.3 · calibrated p 4e-9 ✓ | 96.1 EB05 92.8 · IC025 +6.5 3/3 methods agree | Not in label — unassessed | serious n=2,242 · 100% consumer | no trial arm names this drug |
| Grimacing | 233 | 117.0 100.4–136.5ROR 117.4 · calibrated p 4e-8 ✓ | 81.3 EB05 72.9 · IC025 +5.9 3/3 methods agree | Labeled adverse reaction exact term | serious n=230 | no trial arm names this drug |
| Vaginal flatulence | 80 | 96.8 75.0–125.0ROR 96.9 · calibrated p 2e-7 ✓ | 70.3 EB05 58.3 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious n=80 · ♀ 100% (drug 63%) | no trial arm names this drug |
| Deformity | 2,421 | 95.3 91.0–99.7ROR 98.3 · calibrated p 1e-7 ✓ | 70.6 EB05 68.2 · IC025 +6.1 3/3 methods agree | Not in label — unassessed | serious PRR 52.0 · 100% consumer | no trial arm names this drug |
| Economic problem | 3,961 | 94.6 91.3–98.0ROR 99.7 · calibrated p 1e-7 ✓ | 70.2 EB05 68.4 · IC025 +6.1 3/3 methods agree | Reporting / coding artifact | serious PRR 48.9 · 80% consumer | no trial arm names this drug |
| Nervous system disorder | 7,526 | 86.5 84.4–88.7ROR 95.8 · calibrated p 2e-7 ✓ | 65.7 EB05 64.4 · IC025 +6.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.7 · serious PRR 47.2 · 71% consumer | no trial arm names this drug |
| Neovascularisation | 58 | 79.9 59.6–107.1ROR 80.0 · calibrated p 1e-6 ✓ | 60.7 EB05 48.7 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=58 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Excessive eye blinking | 290 | 66.7 58.6–75.8ROR 66.9 · calibrated p 2e-6 ✓ | 53.4 EB05 48.5 · IC025 +5.4 3/3 methods agree | Not in label — unassessed | serious n=288 · 100% clinician | no trial arm names this drug |
| Disseminated aspergillosis | 79 | 55.3 43.4–70.4ROR 55.3 · calibrated p 9e-6 ✓ | 45.6 EB05 37.7 · IC025 +4.8 3/3 methods agree | Not in label — unassessed | serious n=79 · ♀ 0% (drug 63%) | no trial arm names this drug |
| Quality of life decreased | 2,085 | 50.1 47.9–52.5ROR 51.5 · calibrated p 1e-5 ✓ | 42.4 EB05 40.9 · IC025 +5.3 3/3 methods agree | Not in label — unassessed | serious PRR 33.6 · 100% consumer | no trial arm names this drug |
| Parkinson's disease | 396 | 49.5 44.5–55.1ROR 49.8 · calibrated p 1e-5 ✓ | 41.9 EB05 38.5 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=369 · 100% consumer | no trial arm names this drug |
| Activities of daily living impaired | 2,932 | 46.6 44.9–48.5ROR 48.5 · calibrated p 2e-5 ✓ | 39.9 EB05 38.7 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious PRR 34.4 | no trial arm names this drug |
| Chorea | 244 | 44.8 39.1–51.3ROR 44.9 · calibrated p 3e-5 ✓ | 38.4 EB05 34.5 · IC025 +4.9 3/3 methods agree | Not in label — unassessed | serious n=233 · 100% consumer | no trial arm names this drug |
| Akathisia (inner restlessness) | 1,898 | 44.1 42.0–46.2ROR 45.2 · calibrated p 3e-5 ✓ | 38.0 EB05 36.6 · IC025 +5.2 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 33.7 | no trial arm names this drug |
| Diabetic gastroparesis | 51 | 44.1 32.8–59.3ROR 44.1 · calibrated p 4e-5 ✓ | 37.5 EB05 29.6 · IC025 +4.3 3/3 methods agree | Likely indication confounding term in indications | serious n=48 | no trial arm names this drug |
| Incorrect drug administration duration | 3,710 | 40.8 39.4–42.2ROR 42.8 · calibrated p 3e-5 ✓ | 35.5 EB05 34.6 · IC025 +5.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 0.7 · serious PRR 59.2 · 100% consumer | no trial arm names this drug |
| Essential tremor | 140 | 39.1 32.8–46.7ROR 39.2 · calibrated p 7e-5 ✓ | 34.1 EB05 29.6 · IC025 +4.7 3/3 methods agree | Labeled (related wording) related wording | serious n=132 | no trial arm names this drug |
| Depression suicidal | 369 | 32.5 29.2–36.2ROR 32.7 · calibrated p 2e-4 ✓ | 29.1 EB05 26.7 · IC025 +4.6 3/3 methods agree | Labeled (related wording) related wording | serious n=364 | no trial arm names this drug |
| Computerised tomogram thorax abnormal | 73 | 31.9 25.0–40.7ROR 31.9 · calibrated p 2e-4 ✓ | 28.4 EB05 23.4 · IC025 +4.2 3/3 methods agree | Not in label — unassessed | serious n=73 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Movement disorder | 3,273 | 30.8 29.7–31.9ROR 32.1 · calibrated p 2e-4 ✓ | 27.7 EB05 26.9 · IC025 +4.7 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 1.4 · serious PRR 22.5 · 70% consumer | no trial arm names this drug |
| Protrusion tongue | 56 | 29.2 22.2–38.5ROR 29.2 · calibrated p 4e-4 ✓ | 26.2 EB05 21.0 · IC025 +4.0 3/3 methods agree | Labeled (related wording) related wording | serious n=54 · ♀ 100% (drug 63%) | no trial arm names this drug |
| Stereotypy | 80 | 25.4 20.2–32.0ROR 25.5 · calibrated p 7e-4 ✓ | 23.2 EB05 19.3 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=77 | no trial arm names this drug |
| Multiple drug therapy | 58 | 24.7 18.9–32.3ROR 24.7 · calibrated p 9e-4 ✓ | 22.6 EB05 18.1 · IC025 +3.8 3/3 methods agree | Reporting / coding artifact | serious n=58 · ♀ 100% (drug 63%) · 100% clinician | no trial arm names this drug |
| Dyskinesia (involuntary movements) | 3,221 | 23.5 22.7–24.4ROR 24.5 · calibrated p 7e-4 ✓ | 21.7 EB05 21.1 · IC025 +4.4 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.7 · serious PRR 18.2 | no trial arm names this drug |
| Partner stress | 76 | 23.3 18.4–29.4ROR 23.3 · calibrated p 0.001 ✓ | 21.4 EB05 17.6 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=75 | no trial arm names this drug |
| Anhedonia | 1,798 | 19.8 18.9–20.8ROR 20.3 · calibrated p 0.002 ✓ | 18.6 EB05 17.8 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious PRR 13.2 | no trial arm names this drug |
| Fear | 1,794 | 19.3 18.4–20.3ROR 19.8 · calibrated p 0.002 ✓ | 18.1 EB05 17.4 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | age-adj. PRR 2.1 · serious PRR 15.7 | no trial arm names this drug |
| Parkinsonism | 614 | 18.3 16.9–19.9ROR 18.5 · calibrated p 0.003 ✓ | 17.2 EB05 16.1 · IC025 +4.0 3/3 methods agree | Labeled adverse reaction exact term | serious PRR 12.1 | no trial arm names this drug |
| Metabolic disorder | 359 | 18.0 16.1–20.0ROR 18.0 · calibrated p 0.003 ✓ | 16.9 EB05 15.5 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=335 | no trial arm names this drug |
| Nephrogenic anaemia | 289 | 18.0 15.9–20.2ROR 18.0 · calibrated p 0.003 ✓ | 16.9 EB05 15.3 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=289 | no trial arm names this drug |
| Hyperparathyroidism secondary | 149 | 17.0 14.4–20.1ROR 17.1 · calibrated p 0.004 ✓ | 16.0 EB05 14.0 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=149 | no trial arm names this drug |
| Chronic kidney disease-mineral and bone disorder | 63 | 16.9 13.1–21.9ROR 17.0 · calibrated p 0.005 ✓ | 15.9 EB05 12.8 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=63 | no trial arm names this drug |
| Female genital tract fistula | 99 | 16.6 13.6–20.4ROR 16.6 · calibrated p 0.005 ✓ | 15.7 EB05 13.2 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=98 · ♀ 100% (drug 63%) | no trial arm names this drug |
| Neutropenic sepsis | 376 | 15.1 13.6–16.8ROR 15.2 · calibrated p 0.007 ✓ | 14.3 EB05 13.2 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious PRR 9.2 · 94% clinician | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Extrapyramidal | 19,036 | 60.259.4–61.1 | signal |
| Neutropenia / agranulocytosis | 3,897 | 4.44.2–4.5 | signal |
| Hyponatraemia | 1,084 | 3.73.5–3.9 | signal |
| Anaemia | 2,969 | 2.72.6–2.8 | signal |
| Kidney injury | 4,393 | 2.62.6–2.7 | signal |
| Severe cutaneous reaction | 646 | 2.42.2–2.6 | signal |
| Arrhythmia / qt | 1,658 | 2.42.2–2.5 | signal |
| Thrombocytopenia | 1,874 | 2.32.2–2.4 | signal |
| Pancreatitis | 627 | 2.12.0–2.3 | raised |
| Gi bleeding | 1,390 | 2.12.0–2.2 | raised |
| Depression | 1,993 | 1.91.9–2.0 | raised |
| Serious infection | 5,465 | 1.91.9–2.0 | raised |
| Venous thromboembolism | 1,520 | 1.91.8–2.0 | raised |
| Interstitial lung disease | 666 | 1.91.8–2.1 | raised |
| Anaphylaxis / angioedema | 819 | 1.81.7–1.9 | raised |
| Liver injury | 1,879 | 1.71.6–1.8 | raised |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Tardive dyskinesia (persistent involuntary movements) | 16,218 | 366.3 358.2–374.7ROR 464.3 · calibrated p 1e-13 ✓ | 155.6 EB05 153.6 · IC025 +7.2 3/3 methods agree | Labeled — boxed warning exact term | serious PRR 115.7 · 79% consumer | no trial arm names this drug |
| Extrapyramidal disorder | 12,922 | 293.5 286.5–300.6ROR 352.7 · calibrated p 2e-12 ✓ | 140.8 EB05 138.7 · IC025 +7.1 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 9.3 · serious PRR 97.3 · 71% consumer | no trial arm names this drug |
| Nervous system disorder | 7,526 | 86.5 84.4–88.7ROR 95.8 · calibrated p 2e-7 ✓ | 65.7 EB05 64.4 · IC025 +6.0 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.7 · serious PRR 47.2 · 71% consumer | no trial arm names this drug |
| Dystonia | 7,115 | 158.1 153.7–162.7ROR 174.2 · calibrated p 1e-9 ✓ | 99.9 EB05 98.0 · IC025 +6.6 3/3 methods agree | Not in label — unassessed | serious PRR 69.7 | no trial arm names this drug |
| Nausea | 6,495 | 2.3 2.2–2.3ROR 2.4 · calibrated p 0.867 | 2.3 EB05 2.2 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.6 · serious PRR 2.5 | no trial arm names this drug |
| Pain | 5,972 | 2.7 2.6–2.7ROR 2.8 · calibrated p 0.691 | 2.7 EB05 2.6 · IC025 +1.4 3/3 methods agree | Not in label — unassessed | age-adj. PRR 1.5 · serious PRR 2.6 | no trial arm names this drug |
| Vomiting | 4,944 | 2.9 2.8–3.0ROR 3.0 · calibrated p 0.615 | 2.9 EB05 2.8 · IC025 +1.5 3/3 methods agree | Not in label — unassessed | age-adj. PRR 3.3 · serious PRR 2.5 | no trial arm names this drug |
| Anxiety | 4,099 | 4.0 3.9–4.1ROR 4.1 · calibrated p 0.353 | 3.9 EB05 3.8 · IC025 +1.9 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 3.6 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 4,093 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.822 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 2.0 · serious PRR 1.8 | no trial arm names this drug |
| Economic problem | 3,961 | 94.6 91.3–98.0ROR 99.7 · calibrated p 1e-7 ✓ | 70.2 EB05 68.4 · IC025 +6.1 3/3 methods agree | Reporting / coding artifact | serious PRR 48.9 · 80% consumer | no trial arm names this drug |
| Incorrect drug administration duration | 3,710 | 40.8 39.4–42.2ROR 42.8 · calibrated p 3e-5 ✓ | 35.5 EB05 34.6 · IC025 +5.1 3/3 methods agree | Reporting / coding artifact | age-adj. PRR 0.7 · serious PRR 59.2 · 100% consumer | no trial arm names this drug |
| Fatigue (tiredness) | 3,532 | 1.2 1.2–1.3ROR 1.3 · calibrated p 0.478 | 1.2 EB05 1.2 · IC025 +0.3 | Labeled adverse reaction exact term | age-adj. PRR 1.4 · serious PRR 1.3 | no trial arm names this drug |
| Movement disorder | 3,273 | 30.8 29.7–31.9ROR 32.1 · calibrated p 2e-4 ✓ | 27.7 EB05 26.9 · IC025 +4.7 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 1.4 · serious PRR 22.5 · 70% consumer | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 3,261 | 1.6 1.5–1.6ROR 1.6 · calibrated p 0.710 | 1.6 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 1.3 | no trial arm names this drug |
| Dyskinesia (involuntary movements) | 3,221 | 23.5 22.7–24.4ROR 24.5 · calibrated p 7e-4 ✓ | 21.7 EB05 21.1 · IC025 +4.4 3/3 methods agree | Labeled — boxed warning exact term | age-adj. PRR 3.7 · serious PRR 18.2 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Family stress — n=1,934, PRR 446.1
- Lymphoid tissue hypoplasia — n=84, PRR 358.3
- Thymus hypoplasia — n=85, PRR 268.7
- Dystonia — n=7,115, PRR 158.1
- Multiple injuries — n=2,243, PRR 148.8
- Vaginal flatulence — n=80, PRR 96.8
- Deformity — n=2,421, PRR 95.3
- Neovascularisation — n=58, PRR 79.9
- Excessive eye blinking — n=290, PRR 66.7
- Disseminated aspergillosis — n=79, PRR 55.3
✓ A hand-written Bradford Hill causality assessment exists for this drug: Metoclopramide ↔ Tardive dyskinesia.
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Metoclopramide?
In FDA FAERS, the most frequently co-reported reaction terms for Metoclopramide are tardive dyskinesia, extrapyramidal disorder, nervous system disorder, dystonia, nausea, pain. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Metoclopramide have an FDA boxed warning?
Yes. The current FDA label carries a boxed warning: TARDIVE DYSKINESIA Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. There is no known treatment for TD. The risk of developing TD increases with duration of treatment and total cumulative dosage [ see Warnings and Precautions ( 5.1 ) ].
Do FAERS signals prove that Metoclopramide causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 23f11d3c-1529-4bb6-a61e-e4bab1a3e98e, effective 20240808; matched on
openfda.generic_name.exact:"METOCLOPRAMIDE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,221 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
METOCLOPRAMIDE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.